group (hypoglycaemia, n=3; pyelonephritis, n=1; coronary
artery occlusion, n=1; aortic aneurysm, n=1; bladder calculus,
n=1).
No deaths were reported in patients receiving dapagliflozin.
Four deaths were reported in the group receiving glipizide
(mesenteric infarction, sudden death at home without autopsy,
acute myocardial infarction, road traffic accident).
A total of seven (prostate n=3; breast n=1; gastric n=1;
pancreatic n=2) and three (prostate n=1, skin n=1; lung
n=1) malignancies occurred during the 104-week study
period in the dapagliflozin and glipizide groups, respectively
(Table 2 and Table S2).